Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ELEKTA B

EKTAb.STSE0000163628NASDAQ StockholmSESEK
Stock price
ELEKTA B
Loading chart...

Coverage

Latest articles

Elekta outlines growth strategy, revises order backlog
11 Jun 2025, 19:27EKTAb.STNASDAQ Stockholm

Elekta AB detailed its future growth prospects and the results of a proactive order review at its Investor Update in Stockholm, the company said Tuesday.

Elekta revises order backlog down by 4.9 billion Swedish krona, targets 14% EBIT margin
10 Jun 2025, 09:03EKTAb.STNASDAQ Stockholm

Elekta announced a significant adjustment to its order backlog, cancelling orders valued at 4.9 billion Swedish Krona following a proactive review aimed at improving profitability and predictability.

Elekta names Jakob Just-Bomholt as new President and CEO
9 Jun 2025, 20:29EKTAb.STNASDAQ Stockholm

Elekta has appointed Jakob Just-Bomholt as its new President and CEO, effective September 1, 2025, the medical technology firm announced.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 20:26EKTAb.STNASDAQ Stockholm

Elekta announced Monday the appointment of Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 17:06EKTAb.STNASDAQ Stockholm

Elekta has named Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025, the company announced.

Elekta reports mixed full-year results amid R&D impairment
8 Jun 2025, 20:30EKTAb.STNASDAQ Stockholm

Swedish medical technology firm Elekta reported a net loss of 381 million Swedish Kronor for its fourth quarter, impacted by a 1.064 billion Swedish Kronor non-cash impairment from discontinued research and development projects, the company said.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Invitation to the presentation of Elekta's second quarter 2025/2612 Nov 2025
Elekta's Nomination Committee for the Annual General Meeting 202631 Oct 2025
New impact report reveals radiotherapy's role in cancer care9 Oct 2025
Study shows MRI-guided adaptive radiotherapy with Elekta Unity improves patient-reported urinary symptoms in men with prostate cancer29 Sept 2025
Elekta marks two millionth patient treated with Leksell Gamma Knife radiosurgery25 Sept 2025
Elekta announces changes in Executive Management8 Sept 2025
Report from the Annual General Meeting 2025 of Elekta4 Sept 2025
Interim report, First quarter May-July 2025/2628 Aug 2025
Notice to the Annual General Meeting of Elekta AB (Publ)1 Aug 2025
Elekta receives U.S. FDA 510(k) clearance for its Gamma Knife radiosurgery system to treat patients with refractory, drug-resistant mesial temporal lobe epilepsy23 Jul 2025
Elekta's Annual Report for 2024/25 available4 Jul 2025
Nomination Committee's proposal for the Board of Directors prior to Elekta's Annual General Meeting 202512 Jun 2025
  • Previous
  • 1
  • 2
Search
Company
ELEKTA B
EKTAb.STNASDAQ Stockholm
Website: Unavailable
Coverage
12
  • Next
  • More pages
  • 59
  • Next
  • Filings
    703